Digital Medical Device Regulations Enable Rapid Approvals

Under evolving Digital Medical Device Regulations in Korea, clinical investigation approvals for digital medical devices first exceeded those for traditional devices in 2023, reflecting a structural transition toward software-based technologies that achieve market authorization more rapidly. Digital devices concentrated in Classes 2 and 3 showed a markedly higher share of pivotal investigations aimed at regulatory submission, whereas traditional devices spread across higher-risk Classes 3 and 4 emphasized exploratory work. These patterns indicate that device type influences both study objectives and the duration required to complete the path from plan approval to licensing.

Data Assembly and Comparative Testing

Data integration combined records from the Public Data Portal and the MFDS Medical Device Information Portal to assemble 1,556 clinical investigation plan approvals spanning January 2003 through June 2024. After cleaning, the analytic set contained 1,398 observations, partitioned into 287 digital and 1,111 traditional device investigations. Comparative testing relied on the Mann–Whitney U test for continuous variables and Pearson’s chi-square test for categorical variables, with the Hodges–Lehmann estimator quantifying median differences in approval timelines.

Device-Specific Patterns and Timelines

Digital medical devices displayed an elevated proportion of pivotal investigations (68 percent) and retrospective designs (55 percent), consistent with performance validation of algorithms using existing datasets rather than prospective enrollment. Traditional devices more frequently incorporated randomization, blinding, and concurrent controls, aligning with the need for stepwise safety and performance confirmation in higher-risk hardware. Product-level patterns further differentiated the groups: cognitive therapy software and neural-image diagnostic aids led digital approvals, while biomaterial grafts and electrical stimulation systems dominated traditional approvals, and the mean interval from plan approval to authorization was 181 days shorter for digital devices.

Ad

Stakeholder Consequences Under Updated Rules

Shorter authorization intervals for digital devices suggest that health-technology assessment bodies may encounter compressed evidence-generation windows when evaluating software products for coverage decisions. The predominance of single-center and single-arm designs among digital investigations implies that outcomes researchers will need to adapt indirect-comparison methods or real-world evidence frameworks to support reimbursement submissions. Persistent gaps between high volumes of digital investigation approvals and limited subsequent marketing authorizations highlight the requirement for targeted economic modeling that accounts for both regulatory acceleration and post-approval evidence obligations under the new Digital Medical Product Act, particularly as AI Act implementation challenges and EU AI Act healthcare compliance reshape global standards for software-enabled devices.